GLORIA

GEOMAR Library Ocean Research Information Access

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    The incidence of persistent functioning endometrial tissue following successful radiotherapy for cervical carcinoma (1992)
    238 Main Street, Cambridge, Massachusetts 02142, USA : Blackwell Scientific Publications
    International journal of gynecological cancer 2 (1992), S. 0 
    Details
    ISSN: 1525-1438
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Sixty-three patients under the age of 50 years who were long-term survivors following radiotherapy for cervical cancer and had been placed on hormone replacement therapy (HRT) were identified. The median age at treatment was 37 years and the mean delay from treatment to the initiation of HRT was over 15 months. Fifteen of the 63 patients had experienced vaginal bleeding attributable to the effects of HRT on persisting endometrial tissue. The significance of this is discussed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1525-1438.1992.02060332.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    A short and intensive single-agent cisplatin regimen for recurrent carcinoma of the uterine cervix (1996)
    Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts, 02142, USA : Blackwell Science Inc.
    International journal of gynecological cancer 6 (1996), S. 0 
    Details
    ISSN: 1525-1438
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Between May 1991 and September 1993, 36 patients with recurrent carcinoma of the uterine cervix were treated with single-agent cisplatin using an intensive regimen of four weekly cycles of 50 mg m−2 followed in responders by a further four cycles given every fortnight. The response rate was 47% (95% CI: 27–66%), 56% in those with pelvic recurrence, and 38% in those with metastatic disease. All responses but one were seen within 4 weeks of commencing treatment. Three patients (9%) had a complete response, although in two cases this was of short duration. The treatment was moderately well tolerated and the principle toxicities were myelotoxicity and emesis. The median survival was 32 weeks, and the 18-month survival was 13%.This regimen gives a response rate similar to that seen with more toxic combination chemotherapy regimens such as BIP (bleomycin, ifosfamide and cisplatin). It has the particular advantages of a short duration of treatment and early response, allowing treatment to be stopped after 4 weeks in non-responders. The response rate in pelvic recurrence was better than that seen in most previous chemotherapy trials, particularly as 78% of the evaluable patients with pelvic recurrence had previously received radical radiotherapy to the pelvis.Weekly, followed by fortnightly cisplatin, is an appropriate palliative treatment for patients with recurrent carcinoma of the uterine cervix for whom chemotherapy is indicated.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1525-1438.1996.06010061.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    A new approach to teaching and learning in immunochemistry
    Amsterdam : Elsevier
    Biochemical Education 6 (1978), S. 87-88+99 
    Details
    ISSN: 0307-4412
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    URL: http://linkinghub.elsevier.com/retrieve/pii/0307-4412(78)90010-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin (1997)
    Springer
    Cancer chemotherapy and pharmacology 41 (1997), S. 161-166 
    Details
    ISSN: 1432-0843
    Keywords: Key words Neurotoxicity ; Nimodipine ; Ovarian cancer
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Our previous randomised trial in patients with advanced ovarian cancer indicated a significant response and survival advantage for those receiving high-dose (100 mg/m2) as compared with low-dose (50 mg/m2) cisplatin in combination with cyclophosphamide (750 mg/m2). However, this was accompanied by more toxicity; peripheral neuropathy was troublesome, with 32% of patients experiencing ≥ WHO grade 2 at the cisplatin dose of 100 mg/m2. Nimodipine is a calcium-channel antagonist that has provided protection from cisplatin-induced neurotoxicity in a rat model system. We performed a pilot study in 50 patients that demonstrated the feasibility of co-administration of nimodipine in a chronic oral dosing schedule with cisplatin-based chemotherapy in an open-label non-randomised trial. This led us to initiate a double-blind, placebo-controlled, randomised trial in patients with ovarian cancer, which was prematurely discontinued because of problems with nausea and vomiting, leading to poor patient compliance, that were not predicted by the pilot study. These studies did not demonstrate a neuroprotective effect for nimodipine. The primary efficacy variable, i.e, the neurotoxicity score at the end of treatment, gave a significantly lower mean for placebo patients than for nimodipine patients. This report details our experience and discusses the reasons for premature termination of the randomised trial.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002800050723
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer (1985)
    Springer
    Cancer chemotherapy and pharmacology 14 (1985), S. 272-273 
    Details
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Sixty-six post-menopausal women with metastatic breast cancer were randomised to receive tamoxifen or tamoxifen with aminoglutethimide. The women in the tamoxifen group were virtually free of toxicity, whilst 45% of patients in the aminoglutethimide group had toxicity and 13% discontinued the drug because of this. Responses were seen in 19% of patients receiving tamoxifen alone and 23% of those receiving both drugs. There is no indication that the increased toxicity seen with the addition of aminoglutethimide to tamoxifen in this situation is justified by an increased response rate.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00258132
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Hepatocellular carcinoma after long-term tamoxifen therapy (2000)
    Springer
    Annals of oncology 11 (2000), S. 1195-1196 
    Details
    ISSN: 1569-8041
    Keywords: hepatocellular carcinoma ; tamoxifen
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We describe a case of hepatocellular carcinoma (HCC) after long termtamoxifen therapy in a 71-year-old woman. The patient was prescribed tamoxifenfor 12 years following right mastectomy and axillary node clearance for breastcarcinoma in 1985. In 1997, she complained of abdominal pain and fullness. Anabdominal ultrasound scan showed lesions in the right lobe of liver which werethought to be metastases. However, a biopsy showed primary HCC. Studies inrats suggest that tamoxifen is involved in hepatic carcinogenesis but studiesin humans have failed to show any increased risk. However, these studiesfollowed up patients for less than five years. An increased risk of HCC maynot become apparent until after a decade or more of tamoxifen therapy. Inaddition, HCC in tamoxifen treated patients may be under-reported since theremay be reluctance to biopsy liver tumours which are assumed to be secondarycarcinoma of the breast.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008354429921
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...